| pubmed-article:7247482 | pubmed:abstractText | The latest vaccines for Respiratory Syncytial Virus (RSV) are reviewed. A ts-1 variant is being studied in the attempt to complete the attenuation of the vaccine strain. Further investigations of live RSV vaccine administered parenterally indicate that a target population over 6 months of age could benefit soon of this preparation. | lld:pubmed |
